viewNanoveu Ltd

Nanoveu higher on signing Thai and Malaysian distribution agreements for antiviral protection products

The company has signed agreements with Sanyo Trading Company Ltd for exclusive distribution of its antiviral products.

Nanoveu Ltd - Nanoveu's shares almost 12% higher to 8.6 cents following the signing of Thai and Malaysian distribution agreements
Under the agreement Sanyo will generate orders for Nanoveu’s B2B antiviral film

Nanoveu Ltd’s (ASX:NVU) shares have been almost 18% higher to 9 cents after signing distribution agreements for its antiviral protection products for the Thai and Malaysian markets with Sanyo Trading Company Ltd.

Through these agreements, Sanyo will look to leverage its extensive contacts in the Asia-Pacific region to distribute several Nanoveu’s products to groups including hospitals, banks, schools and shopping malls.

Nanoveu will ship its business to business (B2B) rolls of antiviral film – to be applied to an increasing number of surfaces – in addition to its consumer-focused antiviral mobile phone cases and door handles.

"Proud" to be a partner 

Executive chairman and CEO Alfred Chong said: “Founded in 1947, Sanyo is a name that many consumers in the region are familiar with.

“We are proud that we have been elected to be a partner for such a reputable company which possesses both the reach and capability to distribute our products internationally.”

Highly effective technology 

The company’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses.

It has been proven to eliminate 99.99%1 of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes.

The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2), and coronavirus MHV-A592 .

Sanyo sales director Sandy Yew said: “The spread of disease is a major focus for many countries, including those in the Asia-Pacific region.

“We are excited about brining Nanoveu’s Nanoshield products to our customers, partners and distributors as it represents a credible and proven method of stemming the spread of harmful viruses and bacteria.”

Quick facts: Nanoveu Ltd


Price: 0.041 AUD

Market Cap: $7.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Nanoveu focused on commercialising EyeFyx product following 'revolutionary'...

Nanoveu Ltd's (ASX:NVU) Alfred Chong caught up with Proactive's Andrew Scott after completing what they describe as a revolutionary advanced prototype of its EyeFyx product. It's designed to correct farsightedness for people using digital devices without the need for glasses. The company has...

on 18/11/20

2 min read